Articles related to VISION/OCULAR HEALTH

The FDA classified a recall of 39,060 bottles of Clear Eyes Maximum Itchy Eye Relief as a Class II event after the manufacturer identified sterility concerns and potential contamination affecting a single lot.

Systemic nicotinamide exposure was associated with a lower risk of conversion from ocular hypertension to primary open-angle glaucoma in a large real-world cohort. Patients receiving nicotinamide also had lower rates of topical therapy initiation and laser trabeculoplasty, although the study did not establish causality.

Genetic testing identifies causative variants in approximately 65% to 70% of suspected inherited retinal disease cases and may shorten diagnostic delays. Advances in sequencing technologies and expanding testing access continue to shape retinal disease evaluation and counseling.

The FDA accepted Belite Bio’s NDA for tinlarebant in Stargardt disease type 1 and granted Priority Review. In the phase 3 DRAGON trial, treatment reduced atrophic retinal lesion growth by 35.7% compared with placebo, with regulatory review ongoing.

The FDA classified a voluntary nationwide recall involving nearly 12 million cartons of Rohto Cooling Eye Drops after a lack of assurance of sterility was identified. The action was designated a Class II recall, indicating medically reversible risks or a remote probability of serious harm.

An ophthalmologist-inventor described automated slit-lamp imaging as a way to standardize anterior-segment documentation. The discussion emphasized workflow, ergonomics, teleophthalmology, and future AI training needs.